CTRI/2021/01/030263招募中4 期
A prospective, multi-centric, open-labeled, phase-IV study to assess safety and efficacy of LYFAQUIN™ (Centhaquine citrate) as a resuscitative agent for hypovolemic shock to be used as an adjuvant to standard treatment of shock.
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult males or females aged 18 years or older.
- •2.Patients with hypovolemic shock admitted to the emergency room or ICU with systolic blood pressure = 90 mmHg at presentation and continue to receive standard shock treatment (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the patients shall be the one used in each hospital setup.
- •3.Blood Lactate level indicative of hypovolemic shock with lactate level more than 2 mmol/L.
排除标准
- •1. Development of any other terminal illness not associated with hypovolemic shock during study duration.
- •2. Patient with altered consciousness not due to hypovolemic shock and comatose patient.
- •3. Known pregnancy.
- •4. Cardiopulmonary resuscitation (CPR) before enrollment.
- •5. Presence of a do not resuscitate order.
- •6. Patient is participating in another interventional study.
- •7. Patients with systemic diseases which were already present before having trauma, such as: sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS. Decision to be made by the investigator.
研究者
相似试验
尚未招募
4 期
A non-comparative Phase-IV clinical trial to evaluate safety and efficacy of FDC of Fluoxetine HCl 20mg plus Alprazolam 0.25mg tablet in patients diagnosed with depressive disorderCTRI/2020/05/025240Salute Bestochem Pvt Ltd
已完成
4 期
A Study to Assess safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants with DiabetesCTRI/2020/07/026539Johnson and Johnson Private Limited276
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.EUCTR2013-003579-36-ITBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.EUCTR2013-003579-36-FRBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.RMS and other solid malignant tumors (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) in which treatment with vincristine/irinotecan is considered backbone chemotherapy at relapse and a scientific rationale to combine irinotecan with regorafenib exists.MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-003579-36-GBBayer AG77